Sagliker syndrome: Uglifying human face appearance in late and severe secondary hyperparathyroidism in chronic renal failure

PubMedID: 15490409Almost every patient with chronic renal failure (CRF) eventually develops secondary hyperparathyroidism (SH) unless they are treated with proper and novel medications in advanced medical centers by skilled medical personnel. Every kind of bone abnormality including skull deformities has been described in detail by almost every concerned researcher and textbook, but descriptions of this phenomenon are limited in the medical literature to the years from 1973 to 1977. To our knowledge, extensive data regarding uglifying human face appearances have not been defined so far in the literature. We are therefore making this addition to the clinical nephrology field by accumulating such data. After we found 2 consecutive peculiar and unique patients with uglifying human face appearances in 2000, we attempted to inform and draw attention to this new entity to all hemodialysis (HD) centers in Turkey, as well as in other developing countries around the world to collect data on this phenomenon. Accordingly, we visited dialysis centers and patients' houses to collect detailed information, including medical clinical histories, physical examinations, laboratory data, biographies, current medications, and so forth. We found 25 patients who had CRF, SH, short stature, extremely severe skull changes, maxillary and mandibular bone changes, teeth/dental abnormalities, and soft and innocuous tumoral tissues in the mouth (hence, uglifying the appearance of the face), fingertip changes, severe psychologic problems, and depression. It appears that patients with CRF may have a new syndrome of bone deformities that have long been neglected, ignored, and forgotten since the mid-1970s when they were first described. This is vital and critical information for the clinical status of patients who suffered from the syndrome that we have named Sagliker syndrome (SS), and we believe there are many more patients in the world who are suffering from it. © 2004 Elsevier Inc. All rights reserved

MUTATIONS OF GNAS1, FGF23, FGFR3 GENES IN CKD, SH AND SAGLIKER SYNDROME. A COMBINATION - COMPULSION OF BONE DISPLASIAS - HEREDITARY OSTEODISTROPHIAS AND CKD

WOS: 000383590600389

Sagliker effect (SE) and hypertensionologist hypertension in medical doctors and nurses. Manual BP recordings which is a Harakiri procedure must be banned

14th European Meeting on Hypertension -- JUN 13-17, 2004 -- Paris, FRANCEWOS: 000223099401021

Hypertensionologist' hypertension. Multiple-salvo manual BP recordings-medical harakiri procedures must be banned by legistlations via ESH, ISH and WHO. This phenomenon may be named Sagliker Effect (SE)

18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension -- JUN 14-19, 2008 -- Berlin, GERMANYWOS: 000257197003419…Euorpean Soc Hyperten, Deutsch Hochdrucklig

PRIMAR HYPERTENSION. EARLY NEPHROSCLEROSIS BEGINS FIRST WITHIN THE LEFT KIDNEY. ERGUN'S SIGN

WOS: 000456877501148

Sagliker effect(SE) and hypertensionologist hypertension (HH) in medical doctors and nurses. Multiple-salvo manual BP recordings which are medical Harakiri procedures must be banned by legislation and via ESH, ISH and WHO

15th European Meeting on Hypertension -- JUN 17-21, 2005 -- Milan, ITALYWOS: 000230639802470…European Soc Hypertens, AstraZeneca, Bristol-Myers Squibb Co, Boehringer Ingelheim, MSD, NOVARTIS, RECORDATI, SANKYO, Sanofi Aventis, Bayer Healthcare AG, Pfizer Inc, Solvay Pharmaceut Gmb

TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) IN PERIPHERAL POLYNEUROPATHY IN DIABETES MELLITUS, CHRONIC KIDNEY DISEASE AND PRIMARY HYPERTENSION

WOS: 000456877501043

FIRST MEDICAL WARNING. A REAL HARAKIRI. HYPERTENSIONOLOGIST'S HYPERTENSION. SAGLIKER EFFECT. CLASSICAL MANUAL BP MEASUREMENTS MUST BE BANNED BY LEGISLATIONS AND ESH AND WHO

WOS: 000440355102109

STRIKING EFFICACY OF TRANSCUTANEOUS ELECTRICAL NERVE STIMULATIONS IN PERIPHERAL POLYNEUROPATHIES IN DIABETES MELLITUS II-I, CKD IV-V AND PRIMARY HYPERTENSION

WOS: 000440355102045

Does oral CaCO3 and calcitriol administration for secondary hyperparathyroidism treatment affect the lipid profile in HD patients?

Seventeen patients, 11 males and 6 females, age 39 ± 5.37 years (range 16 63 years), with end-stage renal disease (ESRD) who had been maintained on hemodialysis (HD) for a mean period of 10.4 ± 3.02 months were evaluated for the effects of oral CaCO3 and calcitriol on their lipid profile. All patients received a 40-g protein diet. None of the patients had a weight change or body mass index change (according to the Du Bois calculating table) an the end of the study. During the first 3 months of the study, all subjects were given aluminum-containing phosphate binders (2-3 g/day). Serum HDL, LDL, and total cholesterol, triglyceride, calcium, phosphorus, and alkaline phosphatase levels were measured both at the beginning and at the end of the 3-month period. These measurements were repeated 3 months later following CaCO3 (3 g/day) and calcitriol (0.25 µg/day) therapy. while serum HDL, LDL, and total cholesterol and triglyceride levels were not changed after the administration of aluminum-containing phosphate binders, serum lipid status did improve following the CaCO3 and calcitriol therapy. In conclusion, three months of CaCO3 and calcitriol therapy reduced serum total cholesterol and LDL levels, and LDL/HDL ratios, and this therapy may improve the serum lipid profile to a point similar to the patient with lipid abnormalities but without renal disease